Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials
Background Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
that is closely linked both spatially and temporally to emergence of neurodegeneration and …
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease
Blood‐based markers (BBMs) have recently shown promise to revolutionize the diagnostic
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
and prognostic work‐up of Alzheimer's disease (AD), as well as to improve the design of …
Blood-based biomarkers for Alzheimer's disease: Current state and future use in a transformed global healthcare landscape
Timely detection of the pathophysiological changes and cognitive impairment caused by
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Alzheimer's disease (AD) is increasingly pressing because of the advent of biomarker …
Blood‐based biomarkers for Alzheimer's disease
Neurodegenerative disorders such as Alzheimer's disease (AD) represent a mounting public
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
health challenge. As these diseases are difficult to diagnose clinically, biomarkers of …
Gut microbiome composition may be an indicator of preclinical Alzheimer's disease
Alzheimer's disease (AD) pathology is thought to progress from normal cognition through
preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work …
preclinical disease and ultimately to symptomatic AD with cognitive impairment. Recent work …
Plasma biomarkers for Alzheimer's Disease in relation to neuropathology and cognitive change
Plasma biomarkers related to amyloid, tau, and neurodegeneration (ATN) show great
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …
promise for identifying these pathological features of Alzheimer's Disease (AD) as shown by …
A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for …
The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer's disease: a literature review
AL Brand, PE Lawler, JG Bollinger, Y Li… - Alzheimer's research & …, 2022 - Springer
The extracellular buildup of amyloid beta (Aβ) plaques in the brain is a hallmark of
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …
Alzheimer's disease (AD). Detection of Aβ pathology is essential for AD diagnosis and for …
Plasma proteomic profiles predict future dementia in healthy adults
Y Guo, J You, Y Zhang, WS Liu, YY Huang, YR Zhang… - Nature Aging, 2024 - nature.com
The advent of proteomics offers an unprecedented opportunity to predict dementia onset.
We examined this in data from 52,645 adults without dementia in the UK Biobank, with 1,417 …
We examined this in data from 52,645 adults without dementia in the UK Biobank, with 1,417 …
Dissecting the clinical heterogeneity of early-onset Alzheimer's disease
Early-onset Alzheimer's disease (EOAD) is a rare but particularly devastating form of AD.
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …
Though notable for its high degree of clinical heterogeneity, EOAD is defined by the same …